U.K.-based biotech Alchemab on Tuesday announced a licensing agreement with Eli Lilly (NYSE:LLY) to jointly develop ATLX-1282 ...

The deal builds on an existing research collaboration between Eli Lilly and Alchemab to discover new ALS drugs.

近年来，礼来在生物医药领域动作频频，展现出强大的布局野心。今年 1 月，礼来签订了多项合作协议，其中包括以 7.8 亿美元的授权协议获得 Mediar Therapeutics 公司的特发性肺纤维化药物，以及与 Scorpion ...

Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing ...

Alchemab Therapeutics, whose labs are in Cambridge UK, stands to scoop $415 million from Eli Lilly and Company following a ...

Eli Lilly will be licensing Alchemab Therapeutics’ preclinical programme for amyotrophic lateral sclerosis (ALS) and other ...

Privately-held Alchemab Therapeutics, a biotech that uses the power of human immune evolution to identify and develop ...

Under terms of the deal, Alchemab will lead early Phase I trials for ATLX-1282 in amyotrophic lateral sclerosis, while Lilly ...

Alchemab Therapeutics, a next-gen biopharmaceutical company, has entered into a licensing agreement with Eli Lilly and ...

Financial terms of the new agreement include an upfront payment to secure rights to Alchemab's lead ALS candidate, ATLX-1282, ...

Lilly licenses Alchemab’s ALS antibody ATLX-1282 in $415mn deal, expanding its neuroscience pipeline with a novel, ...